These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29356832)

  • 1. Nine-month clinical outcomes in patients with diabetes treated with polymer-free sirolimus-eluting stents and 6‑month vs. 12‑month dual-antiplatelet therapy (DAPT).
    Krackhardt F; Waliszewski M; Rischner J; Piot C; Pansieri M; Ruiz-Poveda FL; Boxberger M; Noutsias M; Ríos XF; Kherad B
    Herz; 2019 Aug; 44(5):433-439. PubMed ID: 29356832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score matched all comers population treated with ultra-thin strut bare metal and sirolimus-probucol coated drug-eluting stents of identical stent architecture.
    Krackhardt F; Rosli MA; Leschke M; Schneider A; Sperling C; Heang TM; Pons M; Sousa PJ; Kherad B; Waliszewski M
    Catheter Cardiovasc Interv; 2018 Jun; 91(7):1221-1228. PubMed ID: 28944613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease.
    Krackhardt F; Waliszewski M; Kočka V; Toušek P; Janek B; Hudec M; Lozano F; Roman KG; Del Blanco BG; Mauri J; Heang TM; Ahn TH; Jeong MH; Herberger D; Tomulic V; Levy G; Sebagh L; Rischner J; Pansieri M
    Cardiovasc Drugs Ther; 2020 Jun; 34(3):335-344. PubMed ID: 32212061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer-free sirolimus-eluting stents in a large-scale all-comers population.
    Krackhardt F; Kočka V; Waliszewski MW; Utech A; Lustermann M; Hudec M; Studenčan M; Schwefer M; Yu J; Jeong MH; Ahn T; Wan Ahmad WA; Boxberger M; Schneider A; Leschke M
    Open Heart; 2017; 4(2):e000592. PubMed ID: 28761678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 3- to 6-Month Versus 12-Month Dual Antiplatelet Therapy After Coronary Intervention Using the Contemporary Drug-Eluting Stents With Ultrathin Struts: The HOST-IDEA Randomized Clinical Trial.
    Han JK; Hwang D; Yang S; Park SH; Kang J; Yang HM; Park KW; Kang HJ; Koo BK; Hur SH; Kim W; Kim SY; Park SH; Han SH; Kim SH; Shin S; Kim YH; Park K; Lee N; Lee SJ; Kim JW; Kim HS
    Circulation; 2023 May; 147(18):1358-1368. PubMed ID: 36871230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of 6-month versus 12-month dual antiplatelet therapy in patients after implantation of multiple biodegradable polymer-coated sirolimus-eluting coronary stents: Insight from the I-LOVE-IT 2 trial.
    Qi J; Li Y; Li J; Jing Q; Xu K; Gao C; Ma L; Zhang Z; Xu B; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):555-564. PubMed ID: 28318138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in patients needing short dual antiplatelet therapy. Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Godino C; Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Perfetti G; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Fabbiocchi F; Reimers B; Bartorelli A; Colombo A
    Int J Cardiol; 2019 Sep; 290():52-58. PubMed ID: 30917900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent.
    Gallone G; D'Ascenzo F; Boccuzzi G; Cortese B; Di Biasi M; Omedè P; Capodanno D; Cerrato E; Vicinelli P; Infantino V; Poli A; Ugo F; Conrotto F; Grigis G; Varbella F; Latini RA; D'Urbano M; Montabone A; Senatore G; Ferrara E; D'Amico M; De Ferrari GM; Ielasi A
    Catheter Cardiovasc Interv; 2020 Sep; 96(3):E248-E256. PubMed ID: 32012453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice.
    Krackhardt F; Kočka V; Waliszewski M; Toušek P; Janek B; Trenčan M; Krajči P; Lozano F; Roman KG; Otaegui I; Del Blanco BG; Del Olmo VV; Nofrerías EF; Wachowiak L; Heang TM; Ahn TH; Jeong MH; Jung BC; Han KR; Piot C; Sebagh L; Rischner J; Pansieri M; Leschke M
    Medicine (Baltimore); 2020 Feb; 99(8):e19119. PubMed ID: 32080086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-Hospital and 1-Year Clinical Results from the French Registry Using Polymer-Free Sirolimus-Eluting Stents in Acute Coronary Syndrome and Stable Coronary Artery Disease.
    Landolff Q; Quillot M; Picard F; Henry P; Sideris G; Bizeau O; Piot C; Jouve B; Rischner J; Mejri M; Charmasson C; Lasserre R; Pouliquen H; Joseph T; Monsegu J; Karsenty B; Martin Yuste V; Richet N; Lapeyre G; Beverelli F; Beygui F; Koning R
    J Interv Cardiol; 2023; 2023():8907315. PubMed ID: 38125031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
    Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
    Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of 3-Month Dual Antiplatelet Therapy After Implantation of Ultrathin Sirolimus-Eluting Stents With Biodegradable Polymer (Orsiro): Results From the SMART-CHOICE Trial.
    Yun KH; Lee SY; Cho BR; Jang WJ; Song YB; Oh JH; Chun WJ; Park YH; Im ES; Jeong JO; Oh SK; Cho DK; Lee JY; Koh YY; Bae JW; Choi JW; Lee WS; Yoon HJ; Lee SU; Cho JH; Choi WG; Rha SW; Lee JM; Park TK; Yang JH; Choi JH; Choi SH; Lee SH; Gwon HC; Hahn JY;
    J Am Heart Assoc; 2021 Jan; 10(1):e018366. PubMed ID: 33345567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry.
    Lipiecki J; Rampat R; Piot C; Benamer H; Brunelle F; Lefèvre T; El Mahmoud R; Varenne O; Gommeaux A; Malquarti V; Angoulvant D; Cruchon C; Oldroyd K; Spaulding C
    J Invasive Cardiol; 2022 May; 34(5):E363-E368. PubMed ID: 35451995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
    Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
    JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Clinical Outcomes Following Single versus Multivessel Percutaneous Coronary Intervention Using Biodegradable Polymer Coated Sirolimus-Eluting Stent in an All-comers Patient Population.
    Chandwani P; Verma P; Saxena S; Ramachandran PK; Abhyankar A; Sandhu MS; Parikh N; Bhupali A; Jain S; Prajapati J
    Cardiovasc Hematol Agents Med Chem; 2016; 14(1):39-48. PubMed ID: 26585397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.